|
|
|
Currently Enrolling Clinical Trials - Updated November 8, 2009
- Alzheimer's Disease
- These trials use the MMSE (Mini-Mental State
Examination) to determine eligibility by stage of the condition. It should
be administered by a trained individual. MMSE testing is offered in our
clinic free of charge, please use the form below or call us to schedule at
(866) 829-1919.
- Also important is whether or not the patient is taking an approved medication
for Alzheimer's disease: Aricept (donepezil), Razadyne (galantamine), Exelon (rivastigmine), and/or Namenda (memantine). If so, the patient is only
eligible to enter an Add-On trial as listed below.
- All trials are placebo-controlled, which means that a patient may receive a sugar pill and
not an active agent. This is indicated as a percentage. Some offer an open
label extension which follows the first double-blind part and then all patients
continuing into the extension will receive the active agent.
- Most trials offer compensation for travel and meal expenses.
- All trials are subject to the supervision of the FDA regulations for proper conduct and maintenance of safety for human subject participation.
- Phases of trials, as specified by the FDA:
- First time in humans. These are typically for normal volunteers.
- Early clinical experience, with drugs already tested in volunteers.
- For drugs that have a lot of accumulated experience and are aiming for FDA approval
- Post-approval trials.
| Type of Drug |
Phase |
Stage |
MMSE |
Add-On |
Placebo |
Duration |
Open Label |
| Gamma-secretase Inhibitor |
II |
Prodromal/Mild |
24-30 |
AChE not Memantine |
33% |
12 months |
24 months |
| Gamma-secretase Inhibitor |
III |
Mild to Moderate |
16-26 |
Any |
50% |
16 months |
Until approved |
| IV Monoclonal Antibody |
III |
Mild to Moderate |
16-26 |
Any |
50% |
16 months |
Until approved |
| Serotonin receptor 6 antagonist |
II |
Mild to Moderate |
12-24 |
None |
20% |
12 months |
None |
- Epilepsy
- Epilepsy (tendency to have seizures) trials offer medication or devices
to reduce seizure frequency. In some cases they may also test an approach
to delay the progression of the condition.
- If you or someone you know is interested in enrolling, please use the form below.
- For ethical reasons, trials which involve placebo are always Add-On, where a patient
may receive a placebo (sugar pill) he or she will still be taking at least one anti-seizure medication.
| Type of Seizures |
Type of Drug |
Phase |
Add-On |
Placebo |
Duration |
Open Label |
| Partial Seizures |
New anticonvulsant |
III |
Conversion to monotherapy, no VNS |
25% |
12 weeks |
up to 2 years |
| Partial Seizures |
New anticonvulsant |
III |
Yes, VNS OK |
50% |
12 weeks |
up to 5 years |
| Partial Seizures |
New anticonvulsant |
III |
Yes, VNS OK |
50% |
12 weeks |
up to 5 years |
| Partial Seizures |
New anticonvulsant |
III |
Yes, no VNS |
None |
52 weeks |
Until approved |
- Multiple Sclerosis
- Multiple sclerosis trials offer medication to reduce attack frequency. In some cases they may also test an approach
to delay the progression of the condition. Others address symptoms like pain in MS.
- If you or someone you know is interested in enrolling, please use the form below.
| Subtype of MS |
Type of Drug |
Phase |
Add-On |
Placebo |
Duration |
Open Label |
| Relapsing-Remitting |
Oral Immunomodulator |
III |
No |
50% |
24-30 months |
Possible |
| Relapsing-Remitting with Pain |
Serotonin-Noradrenalin Reuptake Inhibitor |
IV |
Yes |
33% |
6 months |
6 months |
If you or a loved one is interested in participating in one of our trials, please
contact us at (866) 829-1919 or use the form below. One of our skilled Clinical Research
Coordinators will contact you as soon as possible. Thank you for your interest in our research!
- Stephen S. Flitman, MD, Principal Investigator
If you are already a patient in the practice and need to reach the doctor on call, do not use this form; call 602-265-6500 directly
|
|
